Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors

Purpose Neurotensin receptor-1 (NTS 1 ) is increasingly recognized as a potential target in diverse tumors including breast cancer, but factors associated with NTS 1 expression have not been fully clarified. Methods We studied NTS 1 expression using the Tissue MicroArray (TMA) of primary breast tumo...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment Vol. 190; no. 3; pp. 403 - 413
Main Authors: Morgat, Clément, Brouste, Véronique, Chastel, Adrien, Vélasco, Valérie, Macgrogan, Gaétan, Hindié, Elif
Format: Journal Article
Language:English
Published: New York Springer US 01.12.2021
Springer
Springer Nature B.V
Springer Verlag
Subjects:
Biological Factors
Breast cancer
Breast Neoplasms - genetics
Cancer research
Cell Line, Tumor
Estrogen receptors
Female
Humans
Life Sciences
Lymph nodes
Medicine
Medicine & Public Health
Metastases
Multivariate analysis
Neurons and Cognition
Neuropeptides
Neurotensin
Oncology
Patients
Preclinical Study
Radiopharmaceuticals
Receptors, Neurotensin - genetics
Tumors
Estrogen receptor
Neuropeptide receptors
Imaging
Targeted radionuclide therapy
Breast cancer
Neurotensin
NTS
NTS1
Cell Line
Biological Factors
Receptors
Humans
Female
Tumor
Radiopharmaceuticals
Breast Neoplasms
ISSN:0167-6806, 1573-7217, 1573-7217
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Neurotensin receptor-1 (NTS 1 ) is increasingly recognized as a potential target in diverse tumors including breast cancer, but factors associated with NTS 1 expression have not been fully clarified. Methods We studied NTS 1 expression using the Tissue MicroArray (TMA) of primary breast tumors from Institut Bergonié. We also studied association between NTS 1 expression and clinical, pathological, and biological parameters, as well as patient outcomes. Results Out of 1419 primary breast tumors, moderate to strong positivity for NTS 1 (≥ 10% of tumoral cells stained) was seen in 459 samples (32.4%). NTS 1 staining was cytoplasmic in 304 tumors and nuclear in 155 tumors, a distribution which appeared mutually exclusive. Cytoplasmic overexpression of NTS 1 was present in 21.5% of all breast tumors. In multivariate analysis, factors associated with cytoplasmic overexpression of NTS 1 in breast cancer samples were higher tumor grade, Ki67 ≥ 20%, and higher pT stage. Cytoplasmic NTS 1 was more frequent in tumors other than luminal A (30% versus 17.3%; p  < 0.0001). Contrastingly, the main “correlates” of a nuclear location of NTS 1 were estrogen receptor (ER) positivity, low E&E (Elston and Ellis) grade, Ki67 < 20%, and lower pT stage. In NTS 1 -positive samples, cytoplasmic expression of NTS 1 was associated with shorter 10-year metastasis-free interval ( p  = 0.033) compared to NTS 1 nuclear staining. Ancillary analysis showed NTS 1 expression in 73% of invaded lymph nodes from NTS 1 -positive primaries. Conclusion NTS 1 overexpression was found in about one-third of breast tumors from patients undergoing primary surgery with two distinct patterns of distribution, cytoplasmic distribution being more frequent in aggressive subtypes. These findings encourage the development of NTS 1 -targeting strategy, including radiopharmaceuticals for imaging and therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0167-6806
1573-7217
1573-7217
DOI:10.1007/s10549-021-06402-5